Announcements Trials

Browse Landscape

Phase

Phase 2 15 Phase 3 4 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Neoplasms, Plasma Cell 1 Multiple Myeloma 1

Interventions

Dexamethasone 132 Lenalidomide 58 Bortezomib 56 Calcium Dobesilate 44 Melphalan 41 carfilzomib 38 pomalidomide 36 Cyclophosphamide 35 daratumumab 23 belantamab mafodotin 21 Peripheral Blood Stem Cell Transplantation 17 ixazomib 16 dexamethasone acetate 13 Filgrastim 13 Bendamustine Hydrochloride 13 fludarabine phosphate 12 fludarabine 12 dexamethasone 21-phosphate 12 Tacrolimus 12 auricularum 11 Whole-Body Irradiation 11 liposomal doxorubicin 10 iberdomide 10 Prednisone 10 venetoclax 9 selinexor 9 isatuximab 9 Mycophenolic Acid 9 pembrolizumab 8 Cyclosporine 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Multiple Myeloma × Clarithromycin × Clear all

NCT02343042 2026-05-04

STOMP

Karyopharm Therapeutics Inc

Phase 1/2 Active not recruiting

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡